STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer

Dinesh Chandra, Wilber Quispe-Tintaya, Arthee Jahangir, Denise Asafu-Adjei, Ilyssa Ramos, Herman O. Sintim, Jie Zhou, Yoshihiro Hayakawa, David K R Karaolis, Claudia Gravekamp

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Cancer vaccination may be our best and most benign option for preventing or treating metastatic cancer. However, breakthroughs are hampered by immune suppression in the tumor microenvironment. In this study, we analyzed whether cyclic diguanylate (c-di-GMP), a ligand for stimulator of interferon genes (STING), could overcome immune suppression and improve vaccination against metastatic breast cancer. Mice with metastatic breast cancer (4T1 model) were therapeutically immunized with an attenuated Listeria monocytogenes (LM)-based vaccine, expressing tumor-associated antigen Mage-b (LM-Mb), followed by multiple low doses of c-di-GMP (0.2 μmol/L). This treatment resulted in a striking and near elimination of all metastases. Experiments revealed that c-di-GMP targets myeloid-derived suppressor cells (MDSC) and tumor cells. Low doses of c-di-GMP significantly increased the production of IL12 by MDSCs, in correlation with improved T-cell responses to Mage-b, whereas a high dose of c-di-GMP (range, 0.3-3 mmol/L) activated caspase-3 in the 4T1 tumor cells and killed the tumor cells directly. On the basis of these results, we tested one administration of high-dose c-di-GMP (3 mmol/L) followed by repeated administrations of low-dose c-di-GMP (0.2 μmol/L) in the 4T1 model, and found equal efficacy compared with the combination of LM-Mb and c-di-GMP. This finding correlated with a mechanism of improved CD8 T-cell responses to tumor-associated antigens (TAA) Mage-b and Survivin, most likely through cross-presentation of these TAAs from c-di-GMP-killed 4T1 tumor cells, and through c-di-GMP-activated TAA-specific T cells. Our results demonstrate that activation of STING-dependent pathways by c-di-GMP is highly attractive for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)901-910
Number of pages10
JournalCancer immunology research
Volume2
Issue number9
DOIs
StatePublished - Sep 1 2014

Fingerprint

Interferons
Vaccination
Breast Neoplasms
Ligands
Genes
Neoplasms
Listeria monocytogenes
Neoplasm Antigens
T-Lymphocytes
bis(3',5')-cyclic diguanylic acid
Cross-Priming
Tumor Microenvironment
Interleukin-12
Caspase 3
Immunotherapy
Vaccines
Neoplasm Metastasis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chandra, D., Quispe-Tintaya, W., Jahangir, A., Asafu-Adjei, D., Ramos, I., Sintim, H. O., ... Gravekamp, C. (2014). STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer immunology research, 2(9), 901-910. https://doi.org/10.1158/2326-6066.CIR-13-0123

STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. / Chandra, Dinesh; Quispe-Tintaya, Wilber; Jahangir, Arthee; Asafu-Adjei, Denise; Ramos, Ilyssa; Sintim, Herman O.; Zhou, Jie; Hayakawa, Yoshihiro; Karaolis, David K R; Gravekamp, Claudia.

In: Cancer immunology research, Vol. 2, No. 9, 01.09.2014, p. 901-910.

Research output: Contribution to journalArticle

Chandra, D, Quispe-Tintaya, W, Jahangir, A, Asafu-Adjei, D, Ramos, I, Sintim, HO, Zhou, J, Hayakawa, Y, Karaolis, DKR & Gravekamp, C 2014, 'STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer', Cancer immunology research, vol. 2, no. 9, pp. 901-910. https://doi.org/10.1158/2326-6066.CIR-13-0123
Chandra D, Quispe-Tintaya W, Jahangir A, Asafu-Adjei D, Ramos I, Sintim HO et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer immunology research. 2014 Sep 1;2(9):901-910. https://doi.org/10.1158/2326-6066.CIR-13-0123
Chandra, Dinesh ; Quispe-Tintaya, Wilber ; Jahangir, Arthee ; Asafu-Adjei, Denise ; Ramos, Ilyssa ; Sintim, Herman O. ; Zhou, Jie ; Hayakawa, Yoshihiro ; Karaolis, David K R ; Gravekamp, Claudia. / STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. In: Cancer immunology research. 2014 ; Vol. 2, No. 9. pp. 901-910.
@article{ea45f8ac82604434beee2bb3f5e0fbea,
title = "STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer",
abstract = "Cancer vaccination may be our best and most benign option for preventing or treating metastatic cancer. However, breakthroughs are hampered by immune suppression in the tumor microenvironment. In this study, we analyzed whether cyclic diguanylate (c-di-GMP), a ligand for stimulator of interferon genes (STING), could overcome immune suppression and improve vaccination against metastatic breast cancer. Mice with metastatic breast cancer (4T1 model) were therapeutically immunized with an attenuated Listeria monocytogenes (LM)-based vaccine, expressing tumor-associated antigen Mage-b (LM-Mb), followed by multiple low doses of c-di-GMP (0.2 μmol/L). This treatment resulted in a striking and near elimination of all metastases. Experiments revealed that c-di-GMP targets myeloid-derived suppressor cells (MDSC) and tumor cells. Low doses of c-di-GMP significantly increased the production of IL12 by MDSCs, in correlation with improved T-cell responses to Mage-b, whereas a high dose of c-di-GMP (range, 0.3-3 mmol/L) activated caspase-3 in the 4T1 tumor cells and killed the tumor cells directly. On the basis of these results, we tested one administration of high-dose c-di-GMP (3 mmol/L) followed by repeated administrations of low-dose c-di-GMP (0.2 μmol/L) in the 4T1 model, and found equal efficacy compared with the combination of LM-Mb and c-di-GMP. This finding correlated with a mechanism of improved CD8 T-cell responses to tumor-associated antigens (TAA) Mage-b and Survivin, most likely through cross-presentation of these TAAs from c-di-GMP-killed 4T1 tumor cells, and through c-di-GMP-activated TAA-specific T cells. Our results demonstrate that activation of STING-dependent pathways by c-di-GMP is highly attractive for cancer immunotherapy.",
author = "Dinesh Chandra and Wilber Quispe-Tintaya and Arthee Jahangir and Denise Asafu-Adjei and Ilyssa Ramos and Sintim, {Herman O.} and Jie Zhou and Yoshihiro Hayakawa and Karaolis, {David K R} and Claudia Gravekamp",
year = "2014",
month = "9",
day = "1",
doi = "10.1158/2326-6066.CIR-13-0123",
language = "English (US)",
volume = "2",
pages = "901--910",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer

AU - Chandra, Dinesh

AU - Quispe-Tintaya, Wilber

AU - Jahangir, Arthee

AU - Asafu-Adjei, Denise

AU - Ramos, Ilyssa

AU - Sintim, Herman O.

AU - Zhou, Jie

AU - Hayakawa, Yoshihiro

AU - Karaolis, David K R

AU - Gravekamp, Claudia

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Cancer vaccination may be our best and most benign option for preventing or treating metastatic cancer. However, breakthroughs are hampered by immune suppression in the tumor microenvironment. In this study, we analyzed whether cyclic diguanylate (c-di-GMP), a ligand for stimulator of interferon genes (STING), could overcome immune suppression and improve vaccination against metastatic breast cancer. Mice with metastatic breast cancer (4T1 model) were therapeutically immunized with an attenuated Listeria monocytogenes (LM)-based vaccine, expressing tumor-associated antigen Mage-b (LM-Mb), followed by multiple low doses of c-di-GMP (0.2 μmol/L). This treatment resulted in a striking and near elimination of all metastases. Experiments revealed that c-di-GMP targets myeloid-derived suppressor cells (MDSC) and tumor cells. Low doses of c-di-GMP significantly increased the production of IL12 by MDSCs, in correlation with improved T-cell responses to Mage-b, whereas a high dose of c-di-GMP (range, 0.3-3 mmol/L) activated caspase-3 in the 4T1 tumor cells and killed the tumor cells directly. On the basis of these results, we tested one administration of high-dose c-di-GMP (3 mmol/L) followed by repeated administrations of low-dose c-di-GMP (0.2 μmol/L) in the 4T1 model, and found equal efficacy compared with the combination of LM-Mb and c-di-GMP. This finding correlated with a mechanism of improved CD8 T-cell responses to tumor-associated antigens (TAA) Mage-b and Survivin, most likely through cross-presentation of these TAAs from c-di-GMP-killed 4T1 tumor cells, and through c-di-GMP-activated TAA-specific T cells. Our results demonstrate that activation of STING-dependent pathways by c-di-GMP is highly attractive for cancer immunotherapy.

AB - Cancer vaccination may be our best and most benign option for preventing or treating metastatic cancer. However, breakthroughs are hampered by immune suppression in the tumor microenvironment. In this study, we analyzed whether cyclic diguanylate (c-di-GMP), a ligand for stimulator of interferon genes (STING), could overcome immune suppression and improve vaccination against metastatic breast cancer. Mice with metastatic breast cancer (4T1 model) were therapeutically immunized with an attenuated Listeria monocytogenes (LM)-based vaccine, expressing tumor-associated antigen Mage-b (LM-Mb), followed by multiple low doses of c-di-GMP (0.2 μmol/L). This treatment resulted in a striking and near elimination of all metastases. Experiments revealed that c-di-GMP targets myeloid-derived suppressor cells (MDSC) and tumor cells. Low doses of c-di-GMP significantly increased the production of IL12 by MDSCs, in correlation with improved T-cell responses to Mage-b, whereas a high dose of c-di-GMP (range, 0.3-3 mmol/L) activated caspase-3 in the 4T1 tumor cells and killed the tumor cells directly. On the basis of these results, we tested one administration of high-dose c-di-GMP (3 mmol/L) followed by repeated administrations of low-dose c-di-GMP (0.2 μmol/L) in the 4T1 model, and found equal efficacy compared with the combination of LM-Mb and c-di-GMP. This finding correlated with a mechanism of improved CD8 T-cell responses to tumor-associated antigens (TAA) Mage-b and Survivin, most likely through cross-presentation of these TAAs from c-di-GMP-killed 4T1 tumor cells, and through c-di-GMP-activated TAA-specific T cells. Our results demonstrate that activation of STING-dependent pathways by c-di-GMP is highly attractive for cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84964313767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964313767&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-13-0123

DO - 10.1158/2326-6066.CIR-13-0123

M3 - Article

C2 - 24913717

AN - SCOPUS:84964313767

VL - 2

SP - 901

EP - 910

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 9

ER -